Rapid-Flow Expulsion Maneuver in Subglottic Secretion Clearance to Prevent Ventilator-Associated Pneumonia: A Randomized Controlled Study

Ying Li  
beijing chaoyang hospital

Xue Yuan  
beijing chaoyang hospital

Bing Sun (✉ ricusunbing@126.com)  
Beijing Chaoyang Hospital  https://orcid.org/0000-0001-9048-9038

Hai-chao Li  
beijing chaoyang hospital

Hui-wen Chu  
beijing chaoyang hospital

Li Wang  
beijing chaoyang hospital

Yu Zhao  
beijing chaoyang hospital

Xiao Tang  
beijing chaoyang hospital

Rui Wang  
Beijing Chaoyang Hospital

Xu-yan Li  
Beijing Chaoyang Hospital

Zhao-hui Tong  
Beijing Chaoyang Hospital

Chen Wang  
beijing chaoyang hospital

Research

Keywords: rapid flow expulsion maneuver, subglottic secretion drainage, ventilator-associated pneumonia

DOI: https://doi.org/10.21203/rs.3.rs-139999/v1
Abstract

**Background:** Following endotracheal intubation, clearing secretions above the endotracheal tube cuff decreases the incidence of ventilator-associated pneumonia (VAP); therefore, subglottic secretion drainage (SSD) is widely advocated. Our group developed a novel technique to remove the subglottic secretions, the rapid-flow expulsion maneuver (RFEM). The objective of this study is to explore the effectiveness and safety of RFEM compared with SSD.

**Methods:** This study was a single center, prospective, randomized and controlled trial, conducted at Respiratory Intensive Care Unit (ICU) of Beijing Chao-Yang Hospital, a university-affiliated tertiary hospital. The primary outcome was the incidence of VAP, assessed for non-inferiority.

**Results:** Patients with an endotracheal tube allowing drainage of subglottic secretions (n=241) were randomly assigned to either the RFEM group (n=120) or SSD group (n=121). Eleven patients (9.17%) in the RFEM group and 13 (10.74%) in the SSD group developed VAP (difference, -1.59; 95% confidence interval [CI], [-9.20 6.03]), as the upper limit of 95% CI was not greater than pre-defined non-inferiority limit(10%), RFEM was declared non-inferior to SSD. There were no statistically significant differences in the duration of mechanical ventilation, ICU mortality, or ICU length of stay and costs between groups. In terms of safety, no accidental extubation or maneuver-related barotrauma occurred in the RFEM group. The incidence of post-extubation laryngeal edema and reintubation was similar in both groups.

**Conclusions:** RFEM is effective and safe, with non-inferiority compared to SSD in terms of the incidence of VAP. RFEM could be an alternative method in first-line treatment of respiratory ICU patients.

Trial registration: This study has been registered on ClinicalTrials.gov (registration number: NCT02032849, https://clinicaltrials.gov/ct2/show/NCT02032849); registered on January 2014.

**Background**

Establishment of an artificial airway is an important treatment approach in critically ill patients, which is commonly complicated by ventilator-associated pneumonia (VAP). Duration of mechanical ventilation, length and cost of time in intensive care unit (ICU), antibiotic treatment and patient mortality are significantly increased by VAP.\(^1\)\(^2\) The main cause of VAP is the accumulation of secretions in the gap between the glottis and the cuff after intubation, which cannot be cleared by coughing. This leads to the spread of pathogens in the lower respiratory tract.\(^3\)

Several studies have confirmed the effectiveness of subglottic secretion drainage (SSD) in reducing the incidence of VAP.\(^4\)^\(^5\) The usage of an endotracheal tube with a subglottic suctioning lumen has been recommended by several VAP prevention guidelines in several countries including the United States, Canada, and China.\(^6\)\(^-\)\(^8\) However, there are still some limitations to this procedure. For example, expensive specialized tubes are required, and the procedure is often accompanied by complications, such as airway mucosal injury, and poor drainage.\(^9\)\(^10\)
Our team has developed an innovative technique to remove subglottic secretions, named the rapid flow expulsion maneuver (RFEM). It uses a manual resuscitator to generate rapid-flow expulsion which can clear the subglottic secretions efficiently. It has been evaluated in in vitro and in vivo pre-trial investigations\textsuperscript{11} and is patented and applied widely in more than 50 ICUs in China since the 1990s. RFEM has been shown to be safe, and cost-effective.\textsuperscript{12,13} Nevertheless, there was still a lack of evidence from large-scale randomized controlled trials (RCT) on the effectiveness of RFEM in preventing VAP.

To obtain further evidence-based support for the wider use of RFEM, we performed this trial to explore the efficacy and safety of RFEM in preventing VAP compared with standard SSD.

**Methods**

**Subjects**

Patients intubated for less than 24 hours in the respiratory ICU and aged 18 years or older were eligible for this trial if they had an estimated survival time > 2 weeks. Patients were excluded if they had: ventilation parameters of positive end-expiratory pressure (PEEP) > 10 cmH\textsubscript{2}O or fraction of inspired oxygen (FiO\textsubscript{2}) > 0.8; hemodynamic instability; history of severe pulmonary blebs with pneumothorax; positive cuff leak test;\textsuperscript{14,15} or had been included in other clinical studies. During the study, patients who were removed from mechanical ventilation after less than 72 hours or for whom treatment was abandoned were also excluded.

**Trial design and randomization**

This was a prospective, single-center, randomized, clinical control trial conducted in the Respiratory ICU at Beijing Chao-Yang Hospital, Capital Medical University (ClinicalTrials.gov, NCT02032849). This study was approved by the Ethics Committee of Beijing Chao-Yang Hospital (2014-KE-106) and informed consent was obtained from the patients or their surrogates.

Randomization was performed using random numbers generated by the random number generator in the SPSS 23.0 statistical software (IBM Corp., Armonk, NY, USA). The enrolled patients (n = 241) were randomly assigned to either the RFEM group (n = 120) or the SSD group (n = 121). Allocation concealment was conducted using sequentially numbered opaque sealed envelopes. This was an unblinded trial because the physicians were aware of the treatment assigned to every participant. However, during the entire study period, the endpoint judgement and the statisticians were blinded.

**Procedures**

All patients enrolled in this study underwent endotracheal intubation along with a subglottic suctioning catheter (TaperGuard\textsuperscript{TM} Evac Oral Tracheal Tube; Medtronic, USA). Clearance of subglottic secretions was performed every 6 hours, and the secretion amounts were recorded.
Rapid-flow expulsion maneuver (RFEM): a manual resuscitator was attached to endotracheal tube and the cuff deflated during the initiation of exhalation, the rapid flow produced by the manual resuscitator passing the space around the deflated cuff was used to remove subglottic secretions from the oropharynx. The complete operational procedure is described in Additional file S1, and video S1 showed how RFEM works.

Subglottic secretion drainage (SSD): A pressure of -100 mmHg with a 15 s duration was applied through a subglottic secretion drainage catheter connected to the sputum collector to carefully suction oral and tracheal secretions while subjects were placed in a semi-recumbent position. If the catheter became blocked, 5 ml of normal saline was instilled through the drainage lumen to maintain its patency.

**Data collection and quality control**

After informed consent was obtained from the study patients, baseline data were recorded: age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score at ICU admission, comorbidities, causes of tracheal intubation and laboratory examinations. Ventilator parameters were also recorded at randomization.

Daily data for a VAP-monitoring form were recorded for each enrolled patient and checked by five respiratory therapists. The diagnosis of VAP was initially made according to the VAP diagnostic criteria (Additional file S2) by two blindly assigned doctors. If the results were inconsistent, a third doctor would participate to establish the diagnosis. Clinical data were recorded on paper case record forms then double-entered into an electronic database and validated by trial staff.

**Endpoints**

The incidence of VAP was the primary endpoint of the study. Patients enrolled in the study were followed-up prospectively for the occurrence of VAP until they received a tracheotomy, were successfully weaned from mechanical ventilation, discharged from the hospital, or died. The per protocol population contains patients who had PEEP below 10 cmH2O or FiO2 below 0.08 at study randomization and needed PEEP above 10 cmH2O or FiO2 above 0.08. These patients were included in the intention-to-treat analysis.

The secondary endpoints included, mechanical ventilation duration, time from intubation to VAP, length of and cost of ICU stay, and mortality while in ICU. The daily volume of subglottic secretions cleared and the need for tracheotomy and reintubation were also recorded.

The safety of RFEM was assessed by recording episodes of pneumothorax, unplanned extubation and changes in vital signs during the maneuver process. Incidence of the post-extubation laryngeal dyspnea in both groups was also evaluated as a safety factor.

**Statistical methods**

**Sample size calculation.** The primary endpoint was evaluated using a non-inferiority analysis. Sample sizes of 120 participants per group achieve 80% power to detect a non-inferiority margin difference
between the group proportions of 0.10, with a one-sided test significance level of 0.05, and a loss to follow-up rate of 10%. Based on the incidence rates of VAP in patients requiring mechanical ventilation in our ICU prior to this study and the results of previous studies,\textsuperscript{17–19} the SSD group proportion is 15%, and the RFEM group proportion is 16.7%.

SPSS 23.0 software (IBM Corp., Armonk, NY, USA) was used for statistical analysis. The level of significance for all statistical tests was 0.05 (two-tailed). The measurement data were presented as means ± SD (standard deviations) or medians and quartile distribution (skewed distribution). Differences between groups were analyzed using the analysis of variance or nonparametric test (skewed distribution). Count data were presented as frequencies and percentages, and differences between groups were tested using the $\chi^2$ test or Fisher’s exact test. VAP-free survival curves in the two groups were displayed graphically according to the Kaplan-Meier method and analyzed using the log-rank test. Univariate and multivariate logistic regression was used to analyze the risk factors for the prevalence of VAP.

Results

Patient Characteristics

From January 2014 to December 2018, 1069 adult patients with mechanical ventilation were admitted to the Respiratory ICU, 806 of whom were excluded according to the selection criteria. In total, 263 cases were randomly assigned to two groups, RFEM and SSD. In the RFEM group, 12 patients were excluded from the data analysis for the primary outcome because they had received mechanical ventilation for less than 72 h. Therefore, 120 patients were included in the RFEM group. In the SSD group, 8 patients had a mechanical ventilation time less than 72 h, and 2 patients tracheoscopy confirmed that drainage failure, and transferred to RFEM. Hence, 121 patients were included in the SSD group (Fig. 1).

There were no statistically significant differences between the two groups on study entry in a variety of factors including demographic data, comorbidities, Apache II or SOFA scores, hemodynamic status and laboratory examinations (Table 1, Table S1). Table 1 lists the causes of tracheal intubation. The main cause for the two groups was respiratory failure (69.17% of the RFEM group and 75.21% of the SSD group) with no significant difference between the groups. The main causes of respiratory failure were pneumonia and exacerbation of chronic obstructive pulmonary disease (Table S2). There were no statistically significant differences in arterial blood gas analysis, respiratory system compliance, or ventilator parameters, including PEEP, tidal volume, and plateau pressure at the time of enrollment (Table 2).
Table 1
Characteristics of study patients at randomization

| Patient Characteristics                      | Total (n = 241) | RFEM (n = 120) | SSD (n = 121) | p     |
|---------------------------------------------|----------------|----------------|---------------|-------|
| Age, years                                  | 61±17          | 63 ± 16        | 58 ± 17       | 0.074 |
| Gender male, n (%)                          | 155 (64.32)    | 76 (63.33)     | 79 (65.29)    | 0.751 |
| Apache II score                             | 16±6           | 16 ± 7         | 16 ± 6        | 0.865 |
| SOFA score                                  | 7±4            | 6 ± 3          | 7 ± 3         | 0.109 |
| Comorbidities, n (%)                        |                |                |               |       |
| Diabetes                                    | 35 (14.52)     | 22 (18.33)     | 13 (10.74)    | 0.095 |
| Chronic respiratory diseases                | 16 (6.64)      | 11 (9.17)      | 5 (4.13)      | 0.117 |
| Cardiovascular diseases                     | 117 (48.55)    | 64 (53.33)     | 53 (43.80)    | 0.139 |
| Chronic renal insufficiency                 | 23 (9.54)      | 13 (10.83)     | 10 (8.26)     | 0.497 |
| Solid tumors                                | 24 (9.96)      | 12 (10.00)     | 12 (9.92)     | 0.983 |
| Hematological neoplasms                    | 16 (6.64)      | 7 (5.83)       | 9 (7.44)      | 0.617 |
| Immunosuppressive therapy                  | 43 (17.84)     | 20 (16.67)     | 23 (19.01)    | 0.635 |
| Causes of tracheal intubation, n (%)        |                |                |               |       |
| Respiratory failure                         | 174 (72.20)    | 83 (69.17)     | 91 (75.21)    | 0.295 |
| Consciousness disorder                      | 41 (17.01)     | 21 (17.50)     | 20 (16.53)    | 0.841 |
| Shock                                       | 7 (2.90)       | 4 (3.33)       | 3 (2.48)      | 0.722 |
| Heart failure                               | 7 (2.90)       | 4 (3.33)       | 3 (2.48)      | 0.722 |
| Other reasons                               | 12 (4.98)      | 7 (5.83)       | 5 (4.13)      | 0.544 |

Definition of abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sequential Organ Failure Assessment.
Table 2
Ventilation function of patients at randomization

| Patient Characteristics | Total (n = 241) | RFEM (n = 120) | SSD (n = 121) | p  |
|-------------------------|---------------|---------------|---------------|----|
| Arterial blood gas analysis |               |               |               |    |
| pH                     | 7.38±0.10     | 7.38 ± 0.10   | 7.38 ± 0.10   | 0.898 |
| PaO₂ (mmHg)            | 76.6±29.9     | 78 ± 34       | 75 ± 25       | 0.357 |
| PaCO₂ (mmHg)           | 49.1±22.3     | 50 ± 24       | 48 ± 20       | 0.335 |
| PaO₂:FiO₂ (mmHg)       | 152.7±87.3    | 163 ± 84      | 147 ± 90      | 0.199 |
| Ventilation parameters |               |               |               |    |
| PEEP (mmH₂O)           | 10(8–10)      | 10(8–10)      | 10(9–10)      | 0.547 |
| Tidal volume (ml/PBM)  | 6.9±2.6       | 7.2±2.9       | 6.7±2.3       | 0.354 |
| Respiratory rate (beats/min) | 30±9   | 29±8          | 31±9          | 0.280 |
| Plateau pressure (cmH₂O) | 25±4   | 24±4          | 26±3          | 0.085 |
| Compliance (ml/cmH₂O)  | 31.2±14.4     | 34.4±16.2     | 28.8±12.6     | 0.124 |

Definition of abbreviations: PaO₂ = partial pressure of arterial oxygen; PaCO₂ = partial pressure of arterial carbon dioxide; PaO₂:FiO₂ = the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen; PEEP = positive end-expiratory pressure; PBM = predicted body weight.

Table S3 compares the risk factors for the development of VAP in both groups. There were no significant differences between the two groups in predisposing conditions.

**Primary endpoint**

In the analysis of the intention-to-treat population, the primary composite endpoint occurred in 11 (9.17%) patients in the RFEM group and in 13 (10.74%) patients in the SSD group, with an absolute risk difference of -1.59% and a one-sided upper 95% confidence limit of 6.03% (p = 0.683 for non-inferiority, Table 3). The cumulative rates of patients remaining VAP-free in the two groups using the Kaplan-Meier curve showed that the rate of VAP-free patients in the RFEM group was numerically higher than that of the SSD group but without a statistically significant difference (log rank test, p = 0.364) (Fig. 2).
Table 3
Outcomes

|                          | RFEM (n = 120) | SSD (n = 121) | Risk difference (95%CI) | p       |
|--------------------------|---------------|---------------|-------------------------|---------|
| Primary endpoint         |               |               |                         |         |
| VAP, n (%)               | 11 (9.17)     | 13 (10.74)    | -1.59 (-9.20, 6.03)     | 0.683   |
| Secondary endpoints      |               |               |                         |         |
| Duration of mechanical ventilation, days | 8 (5–11) | 7 (4–11) | 1 (0, 2) | 0.141 |
| Time from intubation to VAP, days | 7.25±7.94 | 7.92±3.77 | -0.67 (-6.03, 4.69) | 0.793 |
| ICU length of stay, days | 16 (10–25) | 16 (9–26) | 1 (-2, 3) | 0.643 |
| ICU mortality, n (%)     | 36 (30.00)    | 46 (38.02)    | -8.08 (-20.7, 3.91)    | 0.188   |
| ICU expenses, thousand dollars | 12.0 (7.88–19.5) | 13.3 (7.69–25.2) | 0.87 (3.28, 15.1) | 0.465 |
| Volume of subglottic secretions, ml/day | 9.67 (6.78–13.18) | 6.00 (2.10–10.76) | 3.15 (1.42, 4.68) | 0.000 |
| Tracheotomy, n (%)       | 24 (20.00)    | 23 (19.01)    | 1 (-9.08, 11.08)       | 0.846   |
| Reintubation, n (%)      | 12 (10.00)    | 11 (9.09)     | 0.91 (-6.56, 8.4)      | 0.810   |
| Safety assessment, n (%) |               |               |                         |         |
| Barotrauma               | 6 (5.00)      | 10 (8.26)     | -3.29 (-9.61, 3.03)    | 0.309   |
| Pneumothorax             | 5 (83.33)     | 6 (60.00)     | 23.33 (-19.22, 65.89)  | 0.330   |
| Mediastinal emphysema    | 1 (16.67)     | 2 (20.00)     | -3.33 (-42.11, 35.44)  | 0.869   |
| Subcutaneous emphysema   | 1 (16.67)     | 4 (40.00)     | -23.33 (-65.89, 19.22) | 0.330   |
| Post-extubation laryngeal edema | 7 (5.83) | 4 (3.31) | 2.55 (-2.76, 7.86) | 0.347 |

Note: qualitative indicators are expressed by the number of cases (percentage), and 95% CI is calculated by normal approximation method. If the quantitative index obeys normal distribution, it is expressed by mean ± standard deviation, and 95% CI is calculated by t-test method; if it does not obey normal distribution, it is expressed by median (upper quartile - lower quartile), and 95% CI is calculated by Hodges-Lehmann estimation method.

Secondary endpoints

The time from endotracheal intubation to a VAP diagnosis was also similar between the two groups (7.25±7.94 days, 7.92±3.77 days, respectively p = 0.793). There was no significant difference in the
duration of mechanical ventilation, ICU mortality, the length of ICU stay, or ICU cost between the two
groups. ICU mortality was 30.00% in the RFEM group and 38.02% in the SSD group ($p = 0.188$) (Table 3).

The multivariate logistic regression analysis of risk factors associated with VAP showed that only
duration of mechanical ventilation significantly increased the risk of VAP (OR = 1.047, 95% CI 1.008–
1.087, $p = 0.019$). Ventilation duration was $13.3 \pm 7.5$ days in patients developing VAP and $8.9 \pm 7.8$ days
in the others ($p = 0.010$).

Reintubation was required in 12 (10.00%) patients in the RFEM group and 11 (9.09%) patients in the SSD
group without apparent clinical consequences. There was no significant difference in the incidence of
pneumothorax, mediastinal emphysema, or subcutaneous emphysema between the two groups
(Table 3).

SSD was performed at a median of 24 times (16–48 times) per patient and RFEM 32 times (20–48
times) per patient. The median daily volume of subglottic secretions cleared was 9.67 ml (6.78–
13.18 ml) in the RFEM group, significantly higher than that of the SSD group (6.00 ml, 2.10–10.76 ml),
$p < 0.001$.

**Diagnosis of VAP-associated microorganisms**

There also was no significant difference in the etiological distribution between the two groups (Table S4).
Most of the pathogens responsible for VAP in the two groups were Gram-negative bacilli with the
exception of *Streptococcus constellatus* in one patient of the RFEM group. *Acinetobacter baumannii* and
*Pseudomonas aeruginosa* were the most commonly detected pathogens.

**Safety**

In terms of safety, no accidental extubation or maneuver-related barotrauma occurred in the RFEM group.
Changes in vital signs during the process of RFEM were recorded (Table S5). The heart rate, blood
pressure and respiratory rate were significantly increased during the maneuver process of RFEM.
However, during the study, there were only 0.36% (14/3860) episodes of a delayed RFEM owing to
abnormal vital signs. Post-extubation laryngeal edema occurred in 7 (5.83%) patients in the RFEM group
and 4 (3.31%) in the SSD group ($p = 0.347$).

**Discussion**

To the best of our knowledge, this is the first RCT to investigate the efficacy and safety of RFEM in
preventing VAP compared with SSD. The major finding of our study is that there was no significant
difference in the incidence of VAP between the two groups. RFEM can avoid the limitations of SSD, and
we have verified RFEM to be a safe procedure without severe complications.

Several RCTs and meta-analyses show that SSD can significantly reduce the incidence of VAP $^{4,5,18-23}$ In
this study, the incidence of VAP in the SSD group was 10.83%, which was consistent with previous
studies. Jason Powell’s study showed that, especially in critically ill patients, intubation and mechanical ventilation can cause an inflammatory subglottic environment where mucin hyper-secretion and enhanced viscosity is connected with neutrophil infiltration, impairment of neutrophil function, neutrophil elastase release, and enriched VAP-causing pathogens. Enhancement of subglottic mucus removal and/or disruption could be considered a logical target for improved VAP prevention. Other measures have been taken to prevent VAP, including elevating the head of the bed, daily oral hygiene, reducing the use of sedatives and strengthening cuff management. The lower incidence of VAP in the SSD group in our results (10.8%) compared with the predicted incidence of VAP in the sample size calculation (30%) may be due to strict VAP bundles implementation and the fact that the diagnostic criteria for VAP remains a matter of debate. Our study applied a particularly stringent diagnostic criterion which required specific microbiological vigilance (e-Appendix 2).

Multiple studies have found that half of patients have a conventional tracheal tube established prior to ICU admission, which limits the application of SSD. Furthermore, the price of the SSD tube is higher than a conventional tracheal tube. However, some studies have shown that the SSD method is more cost-effective for patients who are on mechanical ventilation > 48 h, but the expected duration of intubation cannot be predicted at the beginning of treatment. In regards to the SSD lumen, the larger outer diameter of the catheter increases the risk of laryngeal injury. Additionally, SSD may cause damage to the tracheal mucosa owing to the focus of negative pressure on the small amount of oropharyngeal secretion gathered above the balloon. An in vitro study indicated that the SSD drainage effect is significantly reduced when the secretion above the cuff balloon was less than 4 ml. Furthermore, the thinner diameter of the drainage tube can result in blockage by thick secretions.

Patients randomized to RFEM had a statistically similar incidence of VAP as patients in the SSD group. However, the RFEM does not require the SSD catheter or other special equipment and is not affected by the quantity and viscosity of the subglottic secretions. Therefore, the amount of daily subglottic secretions removed was greater in the RFEM group. In our study, we found patient heart rate, blood pressure and respiratory rate were significantly increased during the RFEM process. The process of sputum suction could partly explain these increases, as most patients returned to normal after a few minutes. No unplanned extubation or maneuver-related barotrauma occurred, and all conscious patients tolerated the procedure.

The RFEM is effective and safe, and should be an alternative method for hospitals where the SSD catheter has not yet been popularized or for patients without the availability of subglottic suctioning catheters. It is worth noting, however, that RFEM has limitations under certain conditions. For patients requiring high PEEP support (e.g., PEEP > 10 cm H2O), the rapid-flow expulsion might cause the loss of PEEP and the collapse of alveoli when disconnecting patients from the ventilator. Furthermore, it is difficult to push the secretion up to the oropharynx in patients with an upper airway obstruction. Otherwise, patients are supposed to lie in the supine position as much as possible to guarantee the most effective drainage. Additionally, the cooperation of two trained medical professionals is required.
There are several limitations to our study. First, it was a single-center study, the sample size was relatively small, and the main cause of admission was respiratory infection. Second, the ICU expenses calculated in our study did not include the cost of human resource management. Lastly, the two operating procedures, RFEM and SSD, were visually distinguishable, thus the study could not be blinded to physicians and nurses. However, patients were randomized with similar baseline characteristics, and microbiologists blinded to the randomization used strict quantitative microbiological criteria to confirm VAP.

**Conclusions**

In the clearance of subglottic secretions and prevention of VAP, RFEM has efficacy and safety non-inferiority to SSD, and therefore, may serve as an alternative method for SSD. Large multicenter RCTs should be conducted to validate these findings and confirm the cost-effectiveness of RFEM.

**Abbreviations**

APACHE II: Acute Physiology and Chronic Health Evaluation II; ICU: intensive care unit; PEEP: positive end-expiratory pressure; RCT: randomized controlled trials; RFEM: rapid-flow expulsion maneuver; SOFA: sequential organ failure assessment; SSD: subglottic secretion drainage; VAP: ventilator-associated pneumonia.

**Declarations**

**Author contributions**

YL and XY performed the statistical analysis and drafted the manuscript. BS generated the idea and concept for the study, contributed to the data analysis and data interpretation, revised the manuscript, and took responsibility for the integrity of the data. XY, HCL, HWC, LW and YZ recorded and checked data, and performed the SSD and RFEM procedure. RW, XT, CW, ZHT and XYL contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript.

**Acknowledgments**

Not applicable.

**Funding**

This work was supported by Beijing Key Clinical Specialty Excellence Program of 2018 and Beijing Health and Science Technology Achievements and Promotion Program (2018-TG-08).

**Availability of data and materials**

The authors confirm that all data generated or analysed during this study are included in this published article and its supplementary information files.
Ethics approval and consent to participate

This study was approved by the Ethics Committee of Beijing Chao-Yang Hospital and informed consent was obtained from the patients or their surrogates.

Consent for publication

Consent for publication was obtained from all participants.

Competing interests

No authors have potential conflicts to disclose.

References

1. Branch-Elliman W, Wright SB, Howell MD. Determining the ideal strategy for ventilator-associated pneumonia prevention. Cost–benefit analysis. Am J Respir Crit Care Med. 2015;192:57–63.

2. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13:665–71.

3. Powell J, Garnett JP, Mather MW, Cooles FAH, Nelson A, Verdon B, et al. Excess Mucin Impairs Subglottic Epithelial Host Defense in Mechanically Ventilated Patients. Am J Respir Crit Care Med. 2018;198:340–9.

4. Caroff DA, Li L, Muscedere J, Klompas M. Subglottic secretion drainage and objective outcomes: a systematic review and meta-analysis. Crit Care Med. 2016;44:830–40.

5. Mao Z, Gao L, Wang G, Liu C, Zhao Y, Gu W, et al. Subglottic secretion suction for preventing ventilator-associated pneumonia: an updated meta-analysis and trial sequential analysis. Crit Care. 2016;20:353.

6. Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, et al, Society for Healthcare Epidemiology of America (SHEA). Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:915–36.

7. Infection group, respiratory branch, Chinese Medical Association. Guidelines for diagnosis and treatment of hospital acquired pneumonia and ventilator-associated pneumonia in China. Chin J Tuberc Respir Dis. 2018;41:255–80.

8. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D. VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: Prevention. J Crit Care. 2008;23:126–37.

9. Berra L, De Marchi L, Panigada M, Yu ZX, Baccarelli A, Kolobow T. Evaluation of continuous aspiration of subglottic secretion in an in vivo study. Crit Care Med. 2004;32:2071–8.
10. Suys E, Nieboer K, Stiers W, Regt JD, Huyghens L, Spapen H. Intermittent subglottic secretion drainage may cause tracheal damage in patients with few oropharyngeal secretions. Intensive Crit Care Nurs. 2013;29:317–20.

11. Li J, Zong YJ, Zhou Q, Dai H, Wang C. Evaluation of the Safety and Effectiveness of the Rapid Flow Expulsion Maneuver to Clear Subglottic Secretions in Vitro and in Vivo. Respir Care. 2017;62:1007–13.

12. Yang L, Tian WY, Yang YH. Clear the secretions above the cuff. Zhonghua Jie He He Hu Xi Za Zhi. 1994;17:10.

13. Li J, Zhan QY, Liang ZA, Du ML, Dai HP, Sun B, et al. A questionnaire survey on the current practices of respiratory care in intensive care unit in 30 provinces. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009;21:211–4.

14. Miller RL, Cole RP. Association between reduced cuff leak volume and postextubation stridor. Chest. 1996;110:1035–40.

15. Ochoa ME, Marín Md el C, Frutos-Vivar F, Gordo F, Latour-Pérez J, Calvo E, et al. Cuff-leak test for the diagnosis of upper airway obstruction in adults: a systematic review and meta-analysis. Intensive Care Med. 2009;35:1171–9.

16. Mahmoodpoor A, Hamishehkar H, Hamidi M, Shadvar K, Sanaie S, Golzari SE, et al. A prospective randomized trial of tapered-cuff endotracheal tubes with intermittent subglottic suctioning in preventing ventilator-associated pneumonia in critically ill patients. J Crit Care. 2017;38:152–6.

17. Tao Z, Zhao S, Yang G, Wang L, Zhu S. Effect of two methods of subglottic secretion drainage on the incidence of ventilator-associated pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2014;37:283–6.

18. Lacherade JC, De Jonghe B, Guezenne C, Debbat K, Hayon J, Monsel A, et al. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. Am J Respir Crit Care Med. 2010;182:910–7.

19. Damas P, Frippiat F, Ancion A, Canivet JL, Lambermont B, Layios N, et al. Prevention of ventilator-associated pneumonia and ventilator-associated conditions: a randomized controlled trial with subglottic secretion suctioning. Crit Care Med. 2015;43:22–30.

20. Frost SA, Azeem A, Alexandrou E, Tam V, Murphy JK, Hunt L, et al. Subglottic secretion drainage for preventing ventilator associated pneumonia: a meta-analysis. Aust Crit Care. 2013;26:180–8.

21. Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med. 2011;39:1985–91.

22. Deem S, Yanez D, Sissons-Ross L, Broeckel JA, Daniel S, Treggiari M. Randomized pilot trial of two modified endotracheal tubes to prevent ventilator-associated pneumonia. Ann Am Thorac Soc. 2016;13:72–80.

23. Safdari R, Yazdannik A, Abbasi S. Effect of intermittent subglottic secretion drainage on ventilator-associated pneumonia: a clinical trial. Iran J Nurs Midwifery Res. 2014;19:376.
24. Labeau SO, Van de Vyver K, Brusselaers N, Vogelaers D, Blot SI. Prevention of ventilator-associated pneumonia with oral antiseptics: A systematic review and meta-analysis. Lancet Infect Dis. 2011;11:845–54.

25. Nseir S, Lorente L, Ferrer M, Rouzé A, Gonzalez O, Bassi GL, et al. Continuous control of tracheal cuff pressure for VAP prevention: A collaborative meta-analysis of individual participant data. Ann Intensive Care. 2015;5:43.

26. Khan R, Al-Dorzi HM, Al-Attas K, Ahmed FW, Marini AM, Mundekkadan S, et al. The impact of implementing multifaceted interventions on the prevention of ventilator-associated pneumonia. Am J Infect Contr. 2016;44:320–6.

27. Batra P, Mathur P, John NV, Nair SA, Aggarwal R, Soni KD, et al. Impact of multifaceted preventive measures on ventilator-associated pneumonia at a single surgical centre. Intens Care Med. 2015;41:2231–2.

28. Lacherade JC, Azais MA, Pouplet C, Colin G. Subglottic secretion drainage for ventilator-associated pneumonia prevention: an underused efficient measure. Ann Transl Med. 2018;6(21):422.

29. Krein SL, Kowalski CP, Damschroder L, Forman J, Kaufman SR, Saint S. Preventing ventilator-associated pneumonia in the United States: a multicenter mixed-methods study. Infect Control Hosp Epidemiol. 2008;29:933–40.

30. Lorente L, Lecuona M, Jimenez A, Lorenzo L, Roca I, Cabrera J, et al. Continuous endotracheal tube cuff pressure control system protects against ventilator-associated pneumonia. Crit Care. 2014;18:R77.

31. Dragoumanis CK, Vretzakis GI, Papaioannou VE, Didilis VN, Vogiatzaki TD, Pneumatikos IA. Investigating the failure to aspirate subglottic secretions with the Evac endotracheal tube. Anesth Analg. 2007;105:1083–5.

32. Young PJ, Rollinson M, Downward G, Henderson S. Leakage of fluid past the tracheal tube cuff in a benchtop model. Br J Anaesth. 1997;78:557–62.

**Figures**
Figure 1

Flow chart of patients admitted to the respiratory intensive care unit (RICU) between January 2014 and December 2018.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplemental.doc
- VideoS1.compressed.mp4